**Name of journal:** **World Journal of Cardiology**

**ESPS Manuscript NO: 8411**

**Columns: TOPIC HIGHLIGHT**

WJC 6th Anniversary Special Issues (1): Hypertension

**Anti-hypertensive drugs in children and adolescents**

Chu PY *et al*. Anti-hypertensive drugs in children

Patricia Y Chu, Michael J Campbell, Stephen G Miller, Kevin D Hill

**Patricia Y Chu,** Duke Clinical Research Institute, Durham, NC 27715, United States

**Michael J Campbell, Stephen G Miller, Kevin D Hill,** Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27715, United States

**Kevin D Hill,** Duke Clinical Research Institute, Durham, NC 27715, United States

**Author contributions:** Chu PY, Campbell MJ, Miller SG and Hill KD contributed to the manuscript literature review, data compilation and writing.

**Correspondence to: Kevin D Hill, MD, MSCI, Assistant Professor** of Pediatrics in the Division of Pediatric Cardiology, Division of Pediatrics, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Room 7582, Box 3850 Durham, NC, 27705, United States. kevin.hill@duke.edu

**Telephone:** +1-919-6684686  **Fax:** +1-919-6687058

**Received:** December 27, 2013 **Revised:** January 27, 2014

**Accepted:** April 16, 2014

**Published online:**

**Abstract**

Worldwide the prevalence of essential hypertension in children and adolescents continues to increase. Traditionally providers have used “off-label” drugs to treat pediatric hypertension, meaning that rigorous clinical trials of these drugs have not been specifically performed in pediatric patient populations. Consequently providers have extrapolated dosing, safety and efficacy from trials in adults. This practice is sub-optimal as children demonstrate unique differences in drug metabolism and response. Use of unstudied or understudied drugs increases risk of adverse events and/or can lead to sub-optimal efficacy. Recognizing these concerns, regulatory agencies have created financial incentives for industry to conduct pediatric clinical trials. These incentives, coupled with the emerging pediatric hypertension epidemic, have spurred over 30 clinical trials of anti-hypertensive drugs over the past 15 years and have resulted in labeling of 10 new drugs by the United States Food and Drug Administration for treatment of hypertension in children and adolescents. Unfortunately the financial incentive structures focus on newer drugs and drug classes. Consequently there is now a relative dearth of trial data for older but sometimes commonly prescribed pediatric antihypertensive drugs. This article reviews recent pediatric antihypertensive drug trials with a focus on trial design and endpoints, drug dosing, safety, efficacy and specific drug indications. We also review the available data and experience for some of the more commonly prescribed, but less well studied “older” pediatric antihypertensive drugs.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Hypertension; Children; Clinical trials; Dosing; Safety

**Core tip**: This review focuses on the major clinical trials of anti-hypertensive drugs that have been completed over the past 15 years in response to regulatory initiatives by the United States Food and Drug Administration and the European Medicines Agency. These trials have changed the landscape of anti-hypertensive drug management in children.

Chu OY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents.

**Available from:**

**DOI:**

**INTRODUCTION**

Nations throughout the developed world are facing an emerging epidemic of pediatric hypertension that has paralleled an increasing prevalence of childhood obesity[1–5]. In recent cross-sectional studies, greater than one out of every seven US children and adolescents demonstrate prehypertension with over 3% meeting diagnostic criteria for hypertension[6]. Prevalence trends are similar in population-based assessments in numerous other nations[7–11]. Elevated blood pressure during childhood and adolescence is associated with end organ damage[12,13], most commonly left ventricular hypertrophy, and is predictive of hypertension in early adulthood[5,14,15].

With increasing prevalence of pediatric hypertension, there is a need for data supporting safety and efficacy of antihypertensive drugs. While a wide variety of antihypertensive drugs have been studied in clinical trials in adults, traditionally there has been a paucity of evidence to support safety and efficacy of antihypertensive drugs in children and adolescents. Consequently, providers were forced to use drugs “off-label,” extrapolating dosing and efficacy from adult data16. This practice is sub-optimal as children demonstrate unique physiology and pathology, and off-label drug use risks inadequate disease treatment and/or safety events. Furthermore most drugs designed for use in adults do not have pediatric specific tablets or formulations, which can complicate dosing. Recognizing these concerns, regulatory agencies in both the United States and Europe have passed recent regulatory initiatives aimed at stimulating pediatric clinical trials[17,18]. These initiatives have been very successful and over the preceding 15 years, more than 20 clinical trials of anti-hypertensive agents have been completed in children leading to approval of 10 drugs by the United States Federal Drug Administration (FDA) for treatment of hypertension in children and/or adolescents (Figure 1).

This review summarizes the available data and experience supporting the use of antihypertensive drugs in children and adolescents diagnosed with essential hypertension with a particular focus on recent pediatric clinical trials. Angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers and diuretics will be covered with a critical appraisal of available clinical trial data supporting dosing, efficacy, safety, and treatment in specific patient populations. Approval of drugs for pediatric use by the United States FDA will be used as a meaningful benchmark of adequate drug study, reflecting the stringent standards required for FDA approval.

**IDENTIFICATION OF CLINICAL TRIAL DATA**

To identify anti-hypertensive drug trials in children and adolescents, we used four principle sources: the United States FDA website (http://www.accessdata.fda.gov/), the FDA approved drug label, the European Medicines Agency (EMA) website (http://www.ema.europa.eu/) and PubMed. The FDA website and drug label include detailed information summarizing clinical trials completed in response to an FDA issued written request (a requirement for trials completed for drug labeling) including trial design, drug dosing, efficacy and safety data. Similarly the EMA publishes the results of reviews conducted for EMA pediatric drug approval. We also reviewed publications cited on PubMed for relevant clinical trials. Publications were identified following a PubMed search restricted to children and adolescents ≤ 18 years and using MeSH terms “Hypertension” and “clinical trial”.

**ANGIOTENSIN CONVERTING ENZYME INHIBITORS**

Angiotensin converting enzyme (ACE) inhibitors target the renin-angiotensin-aldosterone-system (RAAS). ACE converts angiotensin I to angiotensin II (Ang II), a peptide that causes vasoconstriction and stimulates aldosterone production, itself a potent vasoconstrictor. ACE inhibitors lower blood pressure by decreasing Ang II and mitigating its downstream effects. In adults, ACE inhibitors are commonly used antihypertensives and have the additional benefit of reducing cardiovascular and renal events[19]. In pediatric populations, ACE inhibitors are the most commonly prescribed antihypertensive for both primary and secondary hypertension[20,21]. ACE inhibitors have anti-proteinuric effects and are particularly beneficial in children with chronic kidney disease[22–24] (Table 1). However, similar to adult trials, pediatric trials provide evidence that some ACE inhibitors may be less efficacious in blacks[25–27]. In adult anti-hypertensive trials, side effects associated with use of ACE inhibitors include hyperkalemia, chronic cough and angioedema. In pediatric trials there have been no reports of angioedema and there are fewer reports of cough in pediatric compared to adult trials. However, many of the pediatric trials have been of shorter duration[28]. ACE inhibitors are teratogenic and should be discontinued as soon as pregnancy is detected. ACE inhibitors approved for treatment of pediatric hypertension by the FDA include enalapril, fosinopril, benazepril and lisinopril. Table 2 summarizes the FDA label dosing recommendations that resulted from review of the various pediatric clinical trials of these ACE inhibitors.

***Enalapril*[29]**

Enalapril was the first ACE inhibitor approved by the United States FDA for pediatric hypertension following completion of the required clinical trials in 2002 (Figure 1). Compared to placebo, children treated with moderate or high doses (2.5 or 20 mg for children < 50 kg and 5 mg or 40 mg for children > 50 kg) demonstrated significantly lowered diastolic blood pressure (DBP) and systolic blood pressure (SBP). However, the low dose group (0.625 mg/1.25 mg) did not demonstrate lowering of DBP or SBP. There was no significant difference in antihypertensive effects across race, age, sex, or Tanner stage. Enalapril was well tolerated and safe in the four-week trial. The most common side effects were dizziness (3.6%) and headache (1.8%), and there was only one drug discontinuation (< 1%) due to adverse events. The enalapril FDA label is unique in that the drug has a pediatric indication for all young children with the only exception being neonates.

***Fosinopril*[25,30]**

Fosinopril was approved for treatment of pediatric hypertension by the United States FDA after the trials (including a 52-wk open label safety assessment) were completed in 2003 (Figure 1). In the clinical trials, all three dose levels (0.1, 0.3 and 0.6 mg/kg) of fosinopril were equally effective at reducing SBP and DBP with no dose response in the overall cohort. It remains unclear whether the lack of dose response was attributable to: (1) the dose levels being too high; (2) an overly narrow dose range; or (3) true absence of a dose response. Further analysis showed that fosinopril was effective at reducing SBP in a dose responsive manner in black children however, blacks required a higher dose per body weight to achieve adequate control[25]. Fosinopril was well tolerated with no serious adverse events in the 52-mo open label extension study. Discontinuation of fosinopril secondary to adverse events during the dose ranging and withdrawal phase was rare (1.6%). In the open label extension phase 83% successfully reached target BP with headache (20.1%), nasopharyngitis (9.6%), cough (9.1%), pharyngitis (8.6%), and abdominal pain (6.2%) being the most common adverse events.

***Lisinopril*[31]**

Lisinopril was approved for pediatric hypertension by the United States FDA in 2003. In the pivotal trial (Figure 1), lisinopril demonstrated a dose response reduction in SBP and DBP that was consistent across age groups, tanner stages, and ethnicity. Lisinopril was safe and well tolerated in the four-wk trial with no serious adverse events and few discontinuations (< 1%). The most common adverse events were headache (3.5%), dizziness from hypotension (1.7%), and abdominal pain (1.7%).

***Benazepril*[32]**

Pediatric trials for benazepril have not been published in the literature, but the United States FDA approved it for pediatric hypertension in 2004 and the trials are summarized on the FDA label (Figure 1). Benazepril significantly lowered SBP but did not exhibit a dose response. Benazepril was well tolerated. The FDA label does not report if any patients discontinued the trial due to drug related adverse events.

***Captopril***

Captopril is not approved for treatment of hypertension in children and adolescents, as it is an off-patent agent with no financial incentive for industry to sponsor clinical trials. Because captopril was one of the earliest ACE inhibitors approved for use in adults, there is a substantial body of clinical experience in children and adolescents and several trials have demonstrated clinical efficacy[33,34]. However, a major disadvantage of captopril is the need for frequent dosing (typically three times per day) (Table 3).

**ANGIOTENSIN RECEPTOR BLOCKERS**

Angiotensin receptor blockers (ARBs) target the Angiotensin II Type 1 receptors located on the heart, kidney, blood vessels, and adrenal glands. By blocking the final step of the RAAS, ARBs inhibit vasoconstriction and lower blood pressure[35]. Similar to ACE inhibitors, ARBs are particularly beneficial in reducing left ventricular hypertrophy in adults with heart failure. In adults and children, ARBs are effective at reducing proteinuria secondary to diabetes and may be particularly useful in patients with chronic kidney disease[36–38] (Table 1). However, ARBs are generally less efficacious in African Americans[26,39–42]. Adults who experience cough and cannot tolerate ACE inhibitors often take ARBs as an alternative[43]. ARBs approved for the treatment of pediatric hypertension include losartan, valsartan, candesartan, and olmesartan. Table 2 summarizes the FDA label dosing recommendations that resulted from review of the various pediatric clinical trials of these ARBs. Children tolerated ARBs well, and the side effects most frequently experienced were headache and dizziness.

***Losartan*[38,44]**

Losartan was the first ARB approved for pediatric hypertension by the United States FDA in 2004 following completion of the required clinical trials (Figure 1). Losartan demonstrated a dose response reduction in SBP and DBP with efficacy demonstrated for the moderate and high dose groups (2.5 or 25 mg for children < 50 kg and 5.0 or 50 mg for children ≥ 50 kg) but no significant difference in BP between the low dose Losartan or placebo group. There were too few non-white patients to evaluate race related differences in dose repose. Losartan was well tolerated with few discontinuations due to adverse events (< 1%).

Losartan was also studied in a clinical trial focused on reduction of proteinuria in hypertensive (*n* = 60) and normotensive (*n* = 246) children with chronic kidney disease[38]. Losartan reduced proteinuria by 35.9% (95%CI: 27.6%-43.1%) and was superior to both placebo (normotensive cohort) and amlodipine (hypertensive cohort). Additionally, Losartan reduced SBP and DBP in both cohorts and was superior to amlodipine, although authors postulated that a lack of change in BP in children on amlodipine was due to titration effect. There were no serious adverse events in this trial and 0.7% of subjects discontinued losartan due to adverse events.

***Valsartan*[45]**

Valsartan was approved for pediatric use by the US FDA in 2007. The Valsartan pediatric clinical trials are summarized in Figure 1. Valsartan demonstrated a dose response reduction in SBP and DBP but no statistically significant difference in blood pressure between the low or medium-dose groups (10, 20 mg for children < 35 kg and 20, 40 mg for children ≥ 35 kg). Valsartan’s anti-hypertensive effects were observed across all subgroups including sex, age, tanner stage, and race (black and non-black). During the dose response and withdrawal phase of the study, there were no serious adverse events and few subjects (1.6%) discontinued therapy due to adverse events. Headache (11.6%) and dizziness (2.7%) were the most commonly reported adverse events in the dose response phase. In the 52-wk open label trial, 3.6% of subjects discontinued valsartan due to adverse events. Gastroenteritis (< 1%) and hyperkalemia (< 1%) were the only adverse events considered to be drug-related.

***Candesartan*[46]**

Candesartan was approved for pediatric use by the United States FDA in 2009. Pediatric clinical trials are summarized in Figure 1. In the dose ranging study, Candesartan demonstrated a significant decrease in SBP and DBP compared to placebo at all dose levels but not a dose response. The lack of dose response was attributed to a narrow dose range[46,47]. In the extension study, the 1-year response rate (SBP < 95%) was 52%. Black children had a lesser reduction in SBP and DBP and a lower response rate compared to white children (response rate in black vs. white 43 vs. 61%). Drug discontinuation due to adverse events was rare (1% in dose ranging study and 2.1% in open label study) and there were no serious adverse events.

***Olmesartan*[48]**

Olmesartan was approved for pediatric hypertension by the United States FDA in 2010. In clinical trials (Figure 1) olmesartan demonstrated a dose response reduction in SBP and DBP, but the BP reduction was smaller in blacks. Olmesartan was well tolerated and drug discontinuation due to adverse events was rare (< 1%) with no serious adverse events. The most commonly experienced side effects in the six-week period were headache (1.7%) and dizziness (1.3%).

***Irbesartan*[49,50]**

Irbesartan was not approved for pediatric hypertension due to lack of efficacy. The irbesartan pediatric trials (Figure 1) failed to demonstrate a dose response and although subjects demonstrated statistically significant increases in blood pressure following drug withdrawal, the effect size (+2.3 mg Hg increase in SBP) was small and was not felt to be clinically meaningful. Adverse events were more frequent than in other ARB trials and 2.5% discontinued study drug. There was also one case of erythema multiforme possibly related to irbesartan use.

**CALCIUM CHANNEL BLOCKERS**

Calcium Channel Blockers (CCBs) encompass a diverse group of agents with different targets and functions. Second and third generation dihydropyridine CCBs, such as felodipine and amlodipine, are highly selective for vascular smooth muscle and are commonly prescribed for pediatric hypertension[20,21,51]. They target L Type (long acting) voltage sensitive calcium channels and inhibit further influx of calcium into already depolarized smooth muscle cells, thereby inhibiting actin-myosin activation and muscle contraction[51]. Unlike ACE inhibitors and ARBs, dihydropyridine CCBs do not demonstrate any anti-proteinuric effects in adults[52–54]; however, other studies have shown renoprotective effects in renal transplant patients[55].

Side effects associated with CCBs include gingival hyperplasia and lower extremity edema. Other side effects such as flushing and headache are more commonly associated with immediate release preparations used for acute hypertension. Dihydropyridine CCBs are metabolized/excreted by the liver and dosing can be affected by drugs or compounds that alter CYP metabolism (*e.g.,* Azole antifungals, grapefruit juice)[51]. Pediatric trials have been performed for the CCBs amlodipine and felodipine and FDA dosing recommendations from these trials are summarized in Table 2. Only amlodipine is approved for treatment of pediatric hypertension as felodipine did not demonstrate efficacy.

***Amlodipine*[56]**

Amlodipine was approved for pediatric hypertension by the United States FDA in 2004. It is the most commonly prescribed CCB for pediatric hypertension[21]. In pediatric trials (Figure 1), amlodipine demonstrated a dose response reduction in SBP and DBP. SBP reduction was slightly greater in females compared to males; otherwise, SBP reduction across race, age, and etiology of HTN did not differ significantly. Amlodipine was generally well tolerated with few discontinuations due to adverse events (2.2%). Reasons for discontinuation included worsening hypertension (1.1%), facial edema (< 1%), edema of the fingers with rash (< 1%), and premature ventricular contractions (< 1%). Peripheral edema, an adverse event commonly seen in adults, was reported in 3.8% of children in dose ranging phase and 2.3% of children in placebo withdrawal phase.

***Felodipine ER*[57]**

Felodipine is a long acting calcium channel blocker that has notbeen approved for pediatric HTN due to lack of efficacy. The felodipine pediatric trial included a three-wk dose response trial (*n* = 128) in children with primary hypertension and a 14-wk open label extension period to assess safety. Felodipine was well tolerated (0.8% discontinued due to adverse event) and there were no serious adverse events.

***Nifedipine***

Nifedipine is a calcium channel blocking agent that was previously frequently prescribed to children and adolescents but was off patent and did not qualify for financial incentives and therefore has not been specifically studied for FDA labeling. Data are lacking on efficacy of short acting nifedipine and concerns have been raised about the dosing formulations which can lead to significant blood pressure fluctuations[34,58]. Sustained release nifedipine perhaps has more utility but also has not been formally studied in children and adolescents and therefore must be used “off-label”[34] (Table 3).

**BETA BLOCKERS**

Beta blockers have been used for over 40 years and are recommended for hypertension treatment in adults with coronary artery disease, heart failure, post-myocardial infarction, and diabetes because of their beneficial cardiac effects[59]. Beta blockers lower blood pressure by antagonizing the beta 1 adrenergic receptor located on the myocardium to reduce heart rate and decrease contractility. However, beta blockers may also act on beta 2 adrenergic receptors on the smooth muscle of vasculature and the bronchi, increasing peripheral resistance and risk of bronchospasm[60]. Second generation beta blockers such as metoprolol, bisoprolol, and atenolol are relatively more selective for beta 1 receptors compared to first generation non-selective beta blockers, but at high doses, they may act on beta 2 receptors. Compared to other antihypertensives, first and second generation beta blockers are associated with a higher rate of insulin resistance and new onset diabetes[60–64]. The newest class of beta blockers including carvedilol and nebivolol are vasodilatory and do not appear to have negative effects on metabolic profile[60–63].

Bisoprolol and extended release (XR) metoprolol have been studied in pediatric populations for the treatment of hypertension and their FDA dosing recommendations are summarized in Table 2. In both trials, children with asthma were excluded because of the drugs’ potential broncho-constrictive effects. Bisoprolol did not demonstrate efficacy and, as a result, extended release metoprolol is the only FDA approved beta blocker for pediatric hypertension. Carvedilol has also been studied in pediatric populations but for the treatment of heart failure[65,66]. Efficacy was not demonstrated and, although indicated for treatment of hypertension in adults, carvedilol has never been studied for this indication in children or adolescents. Nonetheless there are data to support dosing of a pediatric formulation[65]. In all pediatric trials of beta blockers drug-related serious adverse events were rare.

***Metoprolol*[67]**

Metoprolol was approved for pediatric hypertension by the United States FDA in 2007.in clinical trials (Figure 1) metoprolol significantly reduced SBP compared to placebo, but with no dose-response effect. Only high doses of XR metoprolol (2 mg/kg) demonstrated significant reductions in DBP compared to placebo. Authors postulated that the lack of dose response reduction in SBP may have been due to a flattening of the dose response curve or a limitation of the study design. At the end of the dose ranging study, the response rate for metoprolol was 46% (95%CI: 37%-55%). Metoprolol’s anti-hypertensive effects were independent of age, Tanner stage, and race. Authors note that overweight patients (BMI > 95%) tended to have less pronounced SBP reductions. Metoprolol was safe and well tolerated with a maximum decrease in heart rate of only 6.5 beats per minute. Drug discontinuation was rare in all trial phases (0.7% in the dose response phase and 5.9% in the open label trial). The most commonly reported adverse events were headache (30%), upper respiratory tract infection (20%), cough (19%), nasopharyngitis (13%), pharyngolarygeal pain (12%), fatigue (9%), diarrhea (7%), and dizziness (6%).

***Bisoprolol fumarate/hydrochlorothiazide*[68]**

Bisoprolol fumarate/hydrochlorothiazide (HCT) (B/HT) is a combination hypertensive that failed to gain United States FDA approval for pediatric hypertension due to lack of efficacy. In a placebo controlled dose ranging pediatric trial (*n* = 94), the percentage of patients in the B/HT group that achieved blood pressure control (SBP and DBP < 90th%) was not significantly different from placebo (45% for B/HT, 34% for placebo). Discontinuation of B/HT due to adverse events was rare (1.6%) and overall fewer adverse events were reported for the B/HT group compared to placebo.

***Propranolol and atenolol***

As some of the oldest beta blockers, propranolol and atenolol fall into the category of off-patent drugs that have not qualified for financial incentives and no large pediatric trials have been performed. As a result, propranolol and atenolol are not labeled for treatment of hypertension in children and adolescents. Most pediatric studies of these beta blockers have been in small case series or for other non-hypertensive indications such as arrhythmias, syncope, hypertrophic cardiac cardiomyopathy, portal hypertension. In these studies, propranolol and atenolol have been effective with acceptable tolerability[34]. Due to the lack of pediatric data, dosing, safety, and efficacy have been extrapolated from adult trials (Table 3).

**DIURETICS**

Most diuretics were off-patent before the implementation in Europe and the United States of financial incentives to conduct pediatric trials. Because off-patent drugs do not qualify for the financial incentives, diuretics represent the class of anti-hypertensive drugs with the least available pediatric clinical trial data. The only diuretic to be tested in a pediatric trial is eplerenone, but it was not approved due to lack of efficacy. Because other diuretics are often used as first line treatment in adults, they will be discussed briefly. Table 3 summarizes generally recognized (albeit not well studied) dosing recommendations for diuretics and select other commonly used antihypertensive drugs that are off-patent and thus have not been studied in clinical trials for FDA or EMA labeling.

Overall, diuretics are a diverse class of drugs that contain some of the oldest and most commonly prescribed agents for adult hypertension[59,69,70]. They can be broadly divided into three categories, thiazide diuretics, loop diuretics, and potassium sparing diuretics. All three classes target different parts of the nephron to decrease sodium and water reabsorption, thereby creating a natriuretic effect that decreases extracellular volume and reduces blood pressure.

***Potassium sparing diuretics***

Potassium sparing diuretics inhibit reabsorption of sodium in the collecting duct and can be further divided into two groups, pteridine analogs and aldosterone antagonists. Pteridine diuretics inhibit epithelial sodium channels (ENaC) and aldosterone antagonist down regulate the Na/K pump and (ENaC) on the collecting duct. Potassium sparing diuretics are often used in conjunction with other potassium losing diuretics to maintain serum potassium levels in a normal range[71,72]. Eplerenone is the only diuretic to be studied for FDA labeling but was not approved. In adults, eplerenone is sometimes preferred over spironolactone because it more selectively binds to aldosterone receptors and does not have unwanted progestational and anti-androgenic effects[72].

***Eplerenone*[73,74]**

 Eplerenone is a selective aldosterone antagonist that was not approved for pediatric hypertension by the United States FDA due to lack of efficacy. The pediatric trial consisted of a six-wk dose ranging study (*n* = 304) and a four-wk dose withdrawal study (*n* = 277). Children on concomitant therapy with a potent CYP3A4 inhibitor (clarithromycin, ketoconazole), potassium supplement, or potassium level > 5.5 mEq/L were excluded and eplerenone is considered contraindicated under such circumstances. In children ages 4 to 17 years old, eplerenone did not demonstrate a dose-response effect and reduced SBP was only seen for the high dose level (50 mg twice a day for children > 20 kg). There was no significant difference in DBP compared to the placebo group. Eplerenone was well tolerated with few serious adverse events (2.6%) or discontinuations in the ten-wk trial (< 1%).

***Thiazide diuretics***

Thiazide diuretics, such as hydrochlorothiazide and chlorthalidone, are first line agents for uncomplicated adult hypertension and are commonly combined with beta blockers, loop diuretics, and ACE inhibitors in multi-drug regimens and in fixed-dose combination formulations[59,75,76]. They are preferred because of their efficacy and superiority in preventing cardiovascular disease compared to other classes of antihypertensives[77]. Thiazides block sodium-chloride co-transporters on the distal convoluted tubule to decrease sodium reabsorption; however, these effects are acute. The exact mechanism by which thiazides reduce peripheral resistance and chronically lower blood pressure is unknown[71,78]. Thiazides are contraindicated in patients with sulfa allergies. Side effects in adults include hypokalemia, hypercalcemia, orthostatic hypotension, worsening of gout (due hyperuricemia), and a worsened metabolic profile (increased rates of new onset diabetes, increase in low density lipoprotein (LDL) cholesterol triglycerides, and glucose)[64,71,78].

***Loop diuretics***

Loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid) are most commonly prescribed in combination with thiazide diuretics for reducing fluid volume in edematous disorders or patients with renal failure[71,79]. There is no data supporting the efficacy of loop diuretics alone to reduce blood pressure. When prescribed alone, loop diuretics lower blood pressure acutely, but not chronically because the activated RAAS will compensate for the lost fluid volume. Loop diuretics inhibit the sodium/potassium/chloride transporter (Na-K-2Cl transporter) on the thick ascending loop of Henle to decrease the osmotic gradient producing a potent natriuretic effect. All loop diuretics, other than ethacrynic acid are contraindicated in patients with sulfa allergies. Side effects in adults associated with loop diuretics include hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia, and worsening of metabolic profile (increased cholesterol, LDL, and triglycerides)[71,80].

**CONCLUSION**

Regulatory initiatives in the United States and Europe over the last one and a half decades have stimulated numerous clinical trials of antihypertensive agents in children. The result has been an increase in the number of United States FDA approved drugs for treatment of pediatric hypertension from zero in 2000 to 11 at present (including esmolol approved for intravenous administration). This is very encouraging with the only caveat that most of the medications studied in pediatric trials belong to newer classes of drugs. There remains a relative dearth of clinical trial data regarding the safety and efficacy of older, commonly used antihypertensive drugs (*e.g.,* diuretics) in children. Nonetheless pediatric providers can now rely on clinical trial data to guide many treatment decisions in children and adolescents with hypertension. FDA labeled antihypertensive drugs have all been safe, efficacious and well tolerated. No deaths and only rare serious adverse events have been reported in clinical trials, albeit most have been of shorter duration. Furthermore, these clinical trials have highlighted the differences between drug safety and efficacy in children versus adults. Many of the approved drugs have demonstrated differences in dosing when compared to adult recommendations and several drugs approved for use in adult patient populations (irbesartan, bisoprolol fumarate/HCTZ, felodipine and eplerenone) have not demonstrated efficacy in pediatric hypertension trials. These data highlight that pediatric drug dosing, safety and efficacy cannot simply be extrapolated from adult clinical trials

As the prevalence of childhood obesity and hypertension continue to rise, it is critical that providers familiarize themselves with these clinical trial data to guide appropriate treatment. Lifestyle changes should continue to form the mainstay of pediatric hypertension therapy; however the importance of medical therapy is increasingly recognized as a means to prevent end-organ damage and hopefully limit the long-term cardiovascular risk associated with hypertension.

**REFERENCES**

1 **Muntner P**, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. *JAMA* 2004; **291**: 2107-2113 [PMID: 15126439 DOI: 10.1001/jama.291.17.2107]

2 **Din-Dzietham R**, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. *Circulation* 2007; **116**: 1488-1496 [PMID: 17846287 DOI: 10.1161/CIRCULATIONAHA.106.683243]

3 **Sorof JM**, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. *Pediatrics* 2004; **113**: 475-482 [PMID: 14993537 DOI: 10.1542/peds.113.3.475]

4 **Falkner B**, Daniels SR. Summary of the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. *Hypertension* 2004; **44**: 387-388 [PMID: 15353515 DOI: 10.1161/01.HYP.0000143545.54637.af]

5 **National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.** The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; **114**: 555-576 [PMID: 15286277 DOI: 10.1542/peds.114.2.S2.555]

6 **McNiece KL**, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. *J Pediatr* 2007; **150**: 640-64, 644.e1 [PMID: 17517252 DOI: 10.1016/j.jpeds.2007.01.052]

7 **Dyson PA**, Anthony D, Fenton B, Matthews DR, Stevens DE. High rates of child hypertension associated with obesity: a community survey in China, India and Mexico. *Paediatr Int Child Health* 2014; **34**: 43-49 [PMID: 24091383 DOI: 10.1179/2046905513Y.0000000079]

8 **Kollias A**, Pantsiotou K, Karpettas N, Roussias L, Stergiou GS. Tracking of blood pressure from childhood to adolescence in a Greek cohort. *Eur J Public Health* 2012; **22**: 389-393 [PMID: 21705785 DOI: 10.1093/eurpub/ckr082]

9 **Lu X**, Shi P, Luo CY, Zhou YF, Yu HT, Guo CY, Wu F. Prevalence of hypertension in overweight and obese children from a large school-based population in Shanghai, China. *BMC Public Health* 2013; **13**: 24 [PMID: 23305064 DOI: 10.1186/1471-2458-13-24]

10 **Mohan B**, Kumar N, Aslam N, Rangbulla A, Kumbkarni S, Sood NK, Wander GS. Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. *Indian Heart J* 2004; **56**: 310-314 [PMID: 15586739]

11 **Reuter ÉM**, Reuter CP, Burgos LT, Reckziegel MB, Nedel FB, Albuquerque IM, Pohl HH, Burgos MS. Obesity and arterial hypertension in schoolchildren from Santa Cruz do Sul--RS, Brazil. *Rev Assoc Med Bras* 2012; **58**: 666-672 [PMID: 23250094]

12 **Daniels SR**, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. *Circulation* 1998; **97**: 1907-1911 [PMID: 9609083 DOI: 10.1161/01.CIR.97.19.1907]

13 **Sorof JM**, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. *Pediatrics* 2003; **111**: 61-66 [PMID: 12509555 DOI: 10.1542/peds.111.1.61]

14 **Bao W**, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens* 1995; **8**: 657-665 [PMID: 7546488 DOI: 10.1016/0895-7061(95)00116-7]

15 **Chen X**, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. *Circulation* 2008; **117**: 3171-3180 [PMID: 18559702 DOI: 10.1161/CIRCULATIONAHA.107.730366]

16 **Yoon EY**, Dombkowski KJ, Rocchini A, Lin JJ, Davis MM. Off-label utilization of antihypertensive medications in children. *Ambul Pediatr* 2007; **7**: 299-303 [PMID: 17660101 DOI: 10.1016/j.ambp.2007.04.005]

17 **Roberts R**, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. *JAMA* 2003; **290**: 905-911 [PMID: 12928467 DOI: 10.1001/jama.290.7.905]

18 **Benjamin DK**, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. *JAMA* 2006; **296**: 1266-1273 [PMID: 16968851 DOI: 10.1001/jama.296.10.1266]

19 **Robles NR**, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. *J Cardiovasc Pharmacol Ther* 2014; **19**: 14-33 [PMID: 24038019 DOI: 10.1177/1074248413501018]

20 **Yoon EY**, Cohn L, Rocchini A, Kershaw D, Freed G, Ascione F, Clark S. Antihypertensive prescribing patterns for adolescents with primary hypertension. *Pediatrics* 2012; **129**: e1-e8 [PMID: 22144698 DOI: 10.1542/peds.2011-0877]

21 **Welch WP**, Yang W, Taylor-Zapata P, Flynn JT. Antihypertensive drug use by children: are the drugs labeled and indicated? *J Clin Hypertens (Greenwich)* 2012; **14**: 388-395 [PMID: 22672093 DOI: 10.1111/j.1751-7176.2012.00656.x]

22 **Simonetti GD**, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. *J Hypertens* 2007; **25**: 2370-2376

23 **Soergel M**, Verho M, Wühl E, Gellermann J, Teichert L, Schärer K. Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. *Pediatr Nephrol* 2000; **15**: 113-118 [PMID: 11095026 DOI: 10.1007/s004670000422]

24 **Seeman T**, Dusek J, Vondrák K, Flögelová H, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. *Am J Hypertens* 2004; **17**: 415-420 [PMID: 15110900 DOI: 10.1016/j.amjhyper.2004.01.008]

25 **Menon S**, Berezny KY, Kilaru R, Benjamin DK, Kay JD, Hazan L, Portman R, Hogg R, Deitchman D, Califf RM, Li JS. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. *Am Heart J* 2006; **152**: 394-399 [PMID: 16875928 DOI: 10.1016/j.ahj.2005.12.025]

26 **Johnson JA**. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. *Circulation* 2008; **118**: 1383-1393 [PMID: 18809808 DOI: 10.1161/CIRCULATIONAHA.107.704023]

27 **Wright JT**, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA* 2005; **293**: 1595-1608 [PMID: 15811979 DOI: 10.1001/jama.293.13.1595]

28 **Baker-Smith CM**, Benjamin DK, Califf RM, Murphy MD, Li JS, Smith PB. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. *Clin Pharmacol Ther* 2010; **87**: 668-671 [PMID: 20130570 DOI: 10.1038/clpt.2009.231]

29 **Wells T**, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. *J Clin Pharmacol* 2002; **42**: 870-880 [PMID: 12162469 DOI: 10.1177/009127002401102786]

30 **Li JS**, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, Jenkins RD, Kanani P, Cottrill CM, Mattoo TK, Zharkova L, Kozlova L, Weisman I, Deitchman D, Califf RM. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? *Hypertension* 2004; **44**: 289-293 [PMID: 15262902 DOI: 10.1161/01.HYP.0000138069.68413.f0]

31 **Soffer B**, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. *Am J Hypertens* 2003; **16**: 795-800 [PMID: 14553956 DOI: 10.1016/S0895-7061(03)00900-2]

32 Lotensin benazepril hydrochloride FDA label. Available at: http://www.accessdata.fda.gov/drugsatfda\_docs/label/2004/019851s028lbl.pdf

33 **Mirkin BL**, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. *Pediatrics* 1985; **75**: 1091-1100 [PMID: 3889818]

34 **Flynn JT**. Management of hypertension in the young: role of antihypertensive medications. *J Cardiovasc Pharmacol* 2011; **58**: 111-120 [PMID: 21242810 DOI: 10.1097/FJC.0b013e31820d1b89]

35 **Burnier M**. Angiotensin II type 1 receptor blockers. *Circulation* 2001; **103**: 904-912 [PMID: 11171802 DOI: 10.1161/01.CIR.103.6.904]

36 **Jessup M**, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation* 2009; **119**: 1977-2016 [PMID: 19324967 DOI: 10.1161/CIRCULATIONAHA.109.192064]

37 KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis* 2012; **60**: 850-886 [PMID: 23067652 DOI: 10.1053/j.ajkd.2012.07.005]

38 **Webb NJ**, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, Santoro E, Manas D, Gleim GW. Randomized, double-blind, controlled study of losartan in children with proteinuria. *Clin J Am Soc Nephrol* 2010; **5**: 417-424 [PMID: 20089489 DOI: 10.2215/CJN.06620909]

39 **Brewster LM**, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. *Ann Intern Med* 2004; **141**: 614-627 [PMID: 15492341 DOI: 10.7326/0003-4819-141-8-200410190-00009]

40 **Flack JM**, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol* 2003; **41**: 1148-1155 [PMID: 12679215 DOI: 10.1016/S0735-1097(03)00054-8]

41 **Jamerson K**, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. *Am J Med* 1996; **101**: 22S-32S [PMID: 8876472 DOI: 10.1016/S0002-9343(96)00265-3]

42 **Cushman WC**, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *Arch Intern Med* 2000; **160**: 825-831 [PMID: 10737282]

43 **Hoy SM**, Keating GM. Candesartan cilexetil: in children and adolescents aged 1 to & lt; 17 years with hypertension. *Am J Cardiovasc Drugs* 2010; **10**: 335-342 [PMID: 20860416 DOI: 10.2165/11206300-000000000-00000]

44 **Shahinfar S**, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, Gleim G, Miller K, Vogt B, Blumer J, Briazgounov I. A double-blind, dose-response study of losartan in hypertensive children. *Am J Hypertens* 2005; **18**: 183-190 [PMID: 15752945 DOI: 10.1016/j.amjhyper.2004.09.009]

45 **Wells T**, Blumer J, Meyers KE, Neto JP, Meneses R, Litwin M, Vande Walle J, Solar-Yohay S, Shi V, Han G. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. *J Clin Hypertens (Greenwich)* 2011; **13**: 357-365 [PMID: 21545397 DOI: 10.1111/j.1751-7176.2011.00432.x]

46 **Trachtman H**, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. *J Clin Hypertens* (Greenwich) 2008; **10**: 743–750

47 **Trachtman H**, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. *J Clin Hypertens (Greenwich)* 2008; **10**: 743-750 [PMID: 19090875 DOI: 10.1111/j.1751-7176.2008.00022.x]

48 **Hazan L**, Hernández Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. *Hypertension* 2010; **55**: 1323-1330 [PMID: 20385971 DOI: 10.1161/HYPERTENSIONAHA.109.147702]

49 Clinical Review: Avapro (Irbesartan) Pediatric efficacy supplement. 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b\_03\_03\_IrbesartanClinicalSummary.pdf

50 Avapro (irbesartan) tablets FDA label. 2005. Available at: http://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/020757s055lbl.pdf

51 **Flynn JT**, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. *Pediatr Nephrol* 2000; **15**: 302-316 [PMID: 11149130 DOI: 10.1007/s004670000480]

52 **Demarie BK**, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. *Ann Intern Med* 1990; **113**: 987-988 [PMID: 2240922 DOI: 10.7326/0003-4819-113-12-987]

53 **Kloke HJ**, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? *Kidney Int* 1998; **53**: 1559-1573 [PMID: 9607186 DOI: 10.1046/j.1523-1755.1998.00912.x]

54 **Janssen JJ**, Gans RO, van der Meulen J, Pijpers R, ter Wee PM. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: a double-blind, randomized prospective study. *Am J Hypertens* 1998; **11**: 1074-1079 [PMID: 9752892 DOI: 10.1016/S0895-7061(98)00129-0]

55 **Silverstein DM**, Palmer J, Baluarte HJ, Brass C, Conley SB, Polinsky MS. Use of calcium-channel blockers in pediatric renal transplant recipients. *Pediatr Transplant* 1999; **3**: 288-292 [PMID: 10562973 DOI: 10.1034/j.1399-3046.1999.00056.x]

56 **Flynn JT**, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, Saul JP. A randomized, placebo-controlled trial of amlodipine in children with hypertension. *J Pediatr* 2004; **145**: 353-359 [PMID: 15343191 DOI: 10.1016/j.jpeds.2004.04.009]

57 **Trachtman H**, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, Tou C, Klibaner M. Clinical trial of extended-release felodipine in pediatric essential hypertension. *Pediatr Nephrol* 2003; **18**: 548-553 [PMID: 12700955 DOI: 10.1007/s00467-003-1134-0]

58 **Adcock KG**, Wilson JT. Nifedipine labeling illustrates the pediatric dilemma for off-patent drugs. *Pediatrics* 2002; **109**: 319-321 [PMID: 11826214 DOI: 10.1542/peds.109.2.319]

59 **Chobanian AV**, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560-2572 [PMID: 12748199 DOI: 10.1001/jama.289.19.2560]

60 **Pedersen ME**, Cockcroft JR. The vasodilatory beta-blockers. *Curr Hypertens Rep* 2007; **9**: 269-277 [PMID: 17686376 DOI: 10.1007/s11906-007-0050-2]

61 **Poirier L**, Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. *Can J Cardiol* 2012; **28**: 334-340 [PMID: 22595449 DOI: 10.1016/j.cjca.2012.04.001]

62 **Ayers K**, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. *Hypertension* 2012; **59**: 893-898 [PMID: 22353614 DOI: 10.1161/HYPERTENSIONAHA.111.189589]

63 **Ram CV**. Beta-blockers in hypertension. *Am J Cardiol* 2010; **106**: 1819-1825 [PMID: 21126627 DOI: 10.1016/j.amjcard.2010.08.023]

64 **Karnes JH**, Cooper-DeHoff RM. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. *Expert Rev Cardiovasc Ther* 2009; **7**: 689-702 [PMID: 19505284 DOI: 10.1586/erc.09.31]

65 Clinical Pharmacology Review: Coreg (Carvedilol) Pediatric Exclusivity Submission. 2006. Available at: http: //www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4344b1\_05\_02\_Coreg BPCA Clinical Pharm Summary.pdf.

66 **Shaddy RE**, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. *JAMA* 2007; **298**: 1171-1179 [PMID: 17848651 DOI: 10.1001/jama.298.10.1171]

67 **Batisky DL**, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, Portman RJ, Falkner B. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. *J Pediatr* 2007; **150**: 134-19, 139.e1 [PMID: 17236889 DOI: 10.1016/j.jpeds.2006.09.034]

68 **Sorof JM**, Cargo P, Graepel J, Humphrey D, King E, Rolf C, Cunningham RJ. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. *Pediatr Nephrol* 2002; **17**: 345-350 [PMID: 12042891 DOI: 10.1007/s00467-002-0851-0]

69 **Rosendorff C**, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. *Circulation* 2007; **115**: 2761-2788 [PMID: 17502569 DOI: 10.1161/CIRCULATIONAHA.107.183885]

70 **Mancia G**, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2007; **28**: 1462-1536 [PMID: 17562668 DOI: 10.1093/eurheartj/ehm236]

71 **Roush GC**, Kaur R, Ernst ME. Diuretics: a review and update. *J Cardiovasc Pharmacol Ther* 2014; **19**: 5-13 [PMID: 24243991 DOI: 10.1177/1074248413497257]

72 **Epstein M**, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. *J Clin Hypertens (Greenwich)* 2011; **13**: 644-648 [PMID: 21896143]

73 **Li JS**, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, Pressler ML. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. *J Pediatr* 2010; **157**: 282-287 [PMID: 20400095 DOI: 10.1016/j.jpeds.2010.02.042]

74 Inspra Eplerenone FDA Label. Available at: http://www.accessdata.fda.gov/drugsatfda\_docs/label/2008/021437s006lbl.pdf.

75 **Wald DS**, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med* 2009; **122**: 290-300 [PMID: 19272490 DOI: 10.1016/j.amjmed.2008.09.038]

76 **Bangalore S**, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007; **120**: 713-719 [PMID: 17679131 DOI: 10.1016/j.amjmed.2006.08.033]

77 **ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; **288**: 2981-2997 [PMID: 12479763 DOI: 10.1001/jama.288.23.2981]

78 **Duarte JD**, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. *Expert Rev Cardiovasc Ther* 2010; **8**: 793-802 [PMID: 20528637 DOI: 10.1586/erc.10.27]

79 **Musini VM**, Rezapour P, Wright JM, Bassett K, Jauca CD. Blood pressure lowering efficacy of loop diuretics for primary hypertension. *Cochrane Database Syst Rev* 2012; **8**: CD003825 [PMID: 22895937 DOI: 10.1002/14651858.CD003825.pub3]

80 **Sica DA**, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. *J Clin Hypertens (Greenwich)* 2011; **13**: 639-643 [PMID: 21896142]

**P-Reviewers:** Guerrero-Romero F, Jiang B **S-Editor:** Gou SX  **L-Editor: E-Editor:**

****

**Figure 1 Timeline for completion of trials that have resulted in Federal Drug Administration labeling for treatment of hypertension in children and adolescents.**

**Table 1 Anti-hypertensive class effects**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug class** | **Special indications** | **Precautions** | **Contraindications** | **Common adverse events** |
| Angiotensin converting enzymeinhibitors | ProteinuriaChronic kidney disease | Less efficacious in blacksRisk of angioedema, Increase risk of hyperkalemiaDecreased glomerular filtration rate | Prior history of angioedema with use of ACE inhibitorDiscontinue if pregnant: Pregnancy Class C in 1st trimester, pregnancy Class D in 2nd and 3rd trimester | HeadacheDizzinessAbdominal painNauseaCough |
| Angiotensin receptor blockers  | Proteinuria | Less efficacious in blacksIncrease risk of hyperkalemiaDecreased GFR | Discontinue if pregnant:Pregnancy Class C in 1st trimester, pregnancy Class D in 2nd and 3rd trimester. | HeadacheDizzinessCough |
| Calcium channel blockers | None | Drug interactions with compounds that change cytochrome P450s metabolism (*i.e.*: azole antifungals, grapefruit juice, anti-seizure medications) | Pregnancy Class C | HeadachePeripheral edemaFatigueDizzinessAbdominal painEpistaxis |
| Beta blockers | None | Increased risk of bronchoconstriction in asthma | Severe bradycardiaHeart block greater than first degreeCardiogenic shockDecompensated cardiac failure | HeadacheCoughNasopharyngitisFatigueDiarrheaDizziness |
| Pregnancy class C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. |
| Pregnancy class D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. |

|  |
| --- |
| **Table 2 Anti-hypertensive drugs that have been studied in pediatric clinical trials for Federal Drug Administration labeling** |
| **Drug class** | **Drug** | **Starting dose** | **Max dose** | **Frequency** | **Suspension formulation** | **Pediatric indication** |
| Angiotensin converting enzyme inhibitor | Enalapril | 0.08 mg/kg (up to 5 mg) | 0.58 mg/kg or 40mg | Daily | Yes | All except neonates |
| Fosinopril | 0.1 mg/kg (5-10 mg) | 0.6mg/kg or 40mg | Daily | No | Children > 50kg |
| Lisinopril | 0.07 mg/kg (up to 5 mg) | 0.6mg/kg or 40mg | Daily | Yes | >6 yr |
| Benazepril | 0.2 mg/kg (up to 10mg) | 0.6mg/kg or 40 mg | Daily | Yes | >6 yr |
| Angiotensin receptor blocker  | Losartan | 0.7 mg/kg (up to 50 mg) | 1.4mg/kg or 100 mg | Daily | Yes | >6 yr |
| Valsartan | 1.3 mg/kg (up to 40mg) | 2.7mg/kg or 160 mg | Daily | Yes | >6 yr |
| Candesartan | 1-6 yr: 0.2mg/kg | 1-6 yr: 0.4 mg/kg | Daily ordivided dose | Yes | >1 yr |
| 6-17 yr, < 50 kg: 4 mg | 6-17yr, < 50 kg: 16 mg |
| 6-17 yrs, > 50 kg 8 mg | 6-17 yrs, > 50 kg 32 mg |
| Olmesartan | 20 to < 35 kg: 10 mg | 20 to < 35 kg: 20 mg | Daily | Yes | >6 yr |
| > 35 kg: 20 mg | > 35 kg: 40 mg |
| Irbesartan | No Federal Drug Administration (FDA) Pediatric Indication (efficacy not demonstrated) |  |
| Beta blocker | Metoprolol XL | 1.0 mg/kg (< 50 mg) | 2 mg/kg up to 200 mg | Daily | No | >6 yr |
| Bisoprolol | No FDA pediatric indication (efficacy not demonstrated) |  |
| Calcium channel blocker | Amlodipine | 2.5 mg | 0.3 mg/kg or 10 mg | Daily | No | >6 yr |
| Felodipine | No FDA pediatric indication (efficacy not demonstrated) |  |
| Diuretic | Eplerenone | No FDA pediatric indication (efficacy not demonstrated) |  |

|  |
| --- |
| **Table 3 Other commonly used “off-label” antihypertensive drugs**1 |
| **Drug class** | **Drug** | **Starting dose** | **Max dose** | **Frequency** |
| Angiotensin converting enzyme inhibitor | Captopril | 0.3-0.5 mg/kg/dose | 6 mg/kg up to 450mg/d | Two to three times daily |
|  |  |  |  |  |
| Beta blocker | Atenolol | 0.5 mg/kg/d | 2 mg/kg/d up to 100mg | Once to twice daily |
| Propranolol | 1mg/kg/d | 16 mg/kg/d up to 640mg | Two to four times daily |
|  |  |  |  |  |
| Calcium channel blocker | Extended release nifedipine | 0.25 mg/kg/d | 3mg/kg/d up 120 mg/kg/d | Once to twice daily |
|  |  |  |  |  |
| Diuretic | Furosemide | 0.5 mg/kg/dose | 6 mg/kg/dose | Twice to three times daily |
| Hydrochlorothiazide | 0.5-1 mg/kg | 3mg/kg up to 50mg | Daily |

1These drugs have not been well studied in pediatric clinical trials and dosing/safety/efficacy are largely extrapolated from trials in adults.